Do analysts recommend IMMX or THAR?

Immix Biopharma presently has a consensus price target of $19.50, indicating a potential upside of 130.77%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, IMMX or THAR?

Immix Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is IMMX or THAR more profitable?

Immix Biopharma's return on equity of -73.24% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Tharimmune N/A -588.45% -264.41%

Do analysts rate THAR or AVTE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, THAR or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is THAR or AVTE more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts recommend THAR or CTNM?

Contineum Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 68.35%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Contineum Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is THAR or CTNM more profitable?

Contineum Therapeutics' return on equity of -27.09% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Contineum Therapeutics N/A -27.09% -25.64%

Do analysts prefer PRTA or THAR?

Prothena currently has a consensus target price of $23.75, suggesting a potential upside of 187.88%. Given Prothena's stronger consensus rating and higher possible upside, equities analysts plainly believe Prothena is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PRTA or THAR more profitable?

Tharimmune has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -260.92% -43.44% -36.87% Tharimmune N/A -588.45% -264.41%

Does the media refer more to PRTA or THAR?

In the previous week, Prothena had 4 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for Prothena and 1 mentions for Tharimmune. Prothena's average media sentiment score of 1.30 beat Tharimmune's score of 0.00 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer EOLS or THAR?

Evolus currently has a consensus target price of $16.00, indicating a potential upside of 137.74%. Given Evolus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Evolus is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EOLS or THAR more profitable?

Tharimmune has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% Tharimmune N/A -588.45% -264.41%

Does the media refer more to EOLS or THAR?

In the previous week, Evolus had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Evolus and 1 mentions for Tharimmune. Evolus' average media sentiment score of 0.93 beat Tharimmune's score of 0.00 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tharimmune (THAR) Competitors

$3.02 +0.07 (+2.37%)

As of 06/11/2026

Compare

THAR vs. IMMX, AVTE, CTNM, PRTA, and EOLS

Should you buy Tharimmune stock or one of its competitors? MarketBeat compares Tharimmune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tharimmune include Immix Biopharma (IMMX), Aerovate Therapeutics (AVTE), Contineum Therapeutics (CTNM), Prothena (PRTA), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry.

How does Tharimmune compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Immix Biopharma has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Immix Biopharma presently has a consensus price target of $19.50, indicating a potential upside of 130.77%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Immix Biopharma is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Immix Biopharma and Immix Biopharma both had 1 articles in the media. Immix Biopharma's average media sentiment score of 1.87 beat Tharimmune's score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Immix Biopharma	Very Positive
Tharimmune	Neutral

Immix Biopharma's return on equity of -73.24% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Tharimmune	N/A	-588.45%	-264.41%

Summary

Immix Biopharma beats Tharimmune on 9 of the 12 factors compared between the two stocks.

How does Tharimmune compare to Aerovate Therapeutics?

Tharimmune (NASDAQ:THAR) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Tharimmune has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, Tharimmune had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Tharimmune and 0 mentions for Aerovate Therapeutics. Tharimmune's average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Tharimmune	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics' return on equity of -90.19% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

1.2% of Tharimmune shares are held by institutional investors. 6.7% of Tharimmune shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Tharimmune beats Aerovate Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Tharimmune compare to Contineum Therapeutics?

Tharimmune (NASDAQ:THAR) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Tharimmune has higher earnings, but lower revenue than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Contineum Therapeutics	$50M	8.88	-$59.98M	-$1.95	N/A

1.2% of Tharimmune shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Contineum Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 68.35%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, Tharimmune and Tharimmune both had 1 articles in the media. Contineum Therapeutics' average media sentiment score of 0.94 beat Tharimmune's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Contineum Therapeutics	Positive

Contineum Therapeutics' return on equity of -27.09% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Summary

Contineum Therapeutics beats Tharimmune on 9 of the 13 factors compared between the two stocks.

How does Tharimmune compare to Prothena?

Prothena (NASDAQ:PRTA) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Tharimmune has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	44.62	-$244.09M	-$2.82	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

97.1% of Prothena shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 6.7% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Prothena currently has a consensus target price of $23.75, suggesting a potential upside of 187.88%. Given Prothena's stronger consensus rating and higher possible upside, equities analysts plainly believe Prothena is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Prothena has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

In the previous week, Prothena had 4 more articles in the media than Tharimmune. MarketBeat recorded 5 mentions for Prothena and 1 mentions for Tharimmune. Prothena's average media sentiment score of 1.30 beat Tharimmune's score of 0.00 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tharimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tharimmune has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Tharimmune	N/A	-588.45%	-264.41%

Summary

Prothena beats Tharimmune on 12 of the 16 factors compared between the two stocks.

How does Tharimmune compare to Evolus?

Evolus (NASDAQ:EOLS) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Evolus currently has a consensus target price of $16.00, indicating a potential upside of 137.74%. Given Evolus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Evolus is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Evolus had 1 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Evolus and 1 mentions for Tharimmune. Evolus' average media sentiment score of 0.93 beat Tharimmune's score of 0.00 indicating that Evolus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tharimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tharimmune has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.49	-$51.64M	-$0.67	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Tharimmune has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Tharimmune	N/A	-588.45%	-264.41%

Evolus has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

90.7% of Evolus shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 5.0% of Evolus shares are held by insiders. Comparatively, 6.7% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Evolus beats Tharimmune on 10 of the 15 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

THAR vs. The Competition

Export

Metric	Tharimmune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$178.84M	$3.39B	$6.75B	$12.02B
Dividend Yield	N/A	2.25%	2.66%	5.61%
P/E Ratio	-0.76	19.48	24.04	24.43
Price / Sales	N/A	304.87	510.75	109.73
Price / Cash	N/A	124.89	44.01	55.64
Price / Book	4.44	8.32	10.66	6.79
Net Income	-$12.20M	$23.89M	$3.56B	$337.66M
7 Day Performance	23.27%	0.94%	0.05%	2.08%
1 Month Performance	-5.33%	-1.16%	0.37%	3.16%
1 Year Performance	120.44%	41.51%	22.73%	27.78%

Tharimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
THAR Tharimmune	0.006 of 5 stars	$3.02 +2.4%	N/A	+87.9%	$178.84M	N/A	N/A	2
IMMX Immix Biopharma	3.4614 of 5 stars	$8.15 -0.4%	$19.50 +139.3%	+233.3%	$443.44M	N/A	N/A	9	Positive News
AVTE Aerovate Therapeutics	N/A	$15.26 +0.3%	N/A	+116.1%	$442.31M	N/A	N/A	20	High Trading Volume
CTNM Contineum Therapeutics	2.3446 of 5 stars	$11.71 +3.6%	$20.00 +70.8%	+159.5%	$437.60M	N/A	N/A	31
PRTA Prothena	2.9905 of 5 stars	$8.29 +4.8%	$23.75 +186.5%	+62.0%	$433.98M	$9.68M	N/A	130	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:THAR) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tharimmune (THAR) Competitors

THAR vs. IMMX, AVTE, CTNM, PRTA, and EOLS

How does Tharimmune compare to Immix Biopharma?

Summary

How does Tharimmune compare to Aerovate Therapeutics?

Summary

How does Tharimmune compare to Contineum Therapeutics?

Summary

How does Tharimmune compare to Prothena?

Summary

How does Tharimmune compare to Evolus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tharimmune (THAR) Competitors

THAR vs. IMMX, AVTE, CTNM, PRTA, and EOLS

How does Tharimmune compare to Immix Biopharma?

Which has more risk & volatility, IMMX or THAR?

Do analysts recommend IMMX or THAR?

Which has higher valuation & earnings, IMMX or THAR?

Do institutionals and insiders have more ownership in IMMX or THAR?

Does the media prefer IMMX or THAR?

Is IMMX or THAR more profitable?

Summary

How does Tharimmune compare to Aerovate Therapeutics?

Which has stronger earnings & valuation, THAR or AVTE?

Which has more volatility and risk, THAR or AVTE?

Does the media favor THAR or AVTE?

Is THAR or AVTE more profitable?

Do analysts rate THAR or AVTE?

Do insiders and institutionals have more ownership in THAR or AVTE?

Summary

How does Tharimmune compare to Contineum Therapeutics?

Which has stronger valuation and earnings, THAR or CTNM?

Do insiders & institutionals have more ownership in THAR or CTNM?

Do analysts recommend THAR or CTNM?

Which has more volatility and risk, THAR or CTNM?

Does the media prefer THAR or CTNM?

Is THAR or CTNM more profitable?

Summary

How does Tharimmune compare to Prothena?

Which has preferable valuation & earnings, PRTA or THAR?

Do institutionals and insiders hold more shares of PRTA or THAR?

Do analysts prefer PRTA or THAR?

Which has more risk & volatility, PRTA or THAR?

Does the media refer more to PRTA or THAR?

Is PRTA or THAR more profitable?

Summary

How does Tharimmune compare to Evolus?

Do analysts prefer EOLS or THAR?

Does the media refer more to EOLS or THAR?

Which has better valuation & earnings, EOLS or THAR?

Is EOLS or THAR more profitable?

Which has more risk and volatility, EOLS or THAR?

Do insiders & institutionals believe in EOLS or THAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

THAR vs. The Competition

Tharimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools